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Abstract 1 
Background: Sepsis remains a major cause of mortality in critical care, for which specific 2 
treatments are lacking. The dysregulated response to infection seen in sepsis includes 3 
features of lymphocyte dysfunction and exhaustion, suggesting that immune-stimulatory 4 
therapy may improve outcomes in certain patient groups. Monoclonal antibodies targeting 5 
checkpoint molecules, such as programmed-death 1 protein (PD-1) and its ligand PD-L1, 6 
have shown success in stimulating the immune response in cancer patients, and are being 7 
considered for future sepsis trials. The aims of this pilot study were to compare lymphocyte 8 
subset expression of PD-1 and its ligands between sepsis patients and controls; to 9 
characterize serum levels of PD-1 and PD-L1 in sepsis patients and controls, and determine if 10 
serum concentrations correlated with cell surface expression. 11 
Methods: Expression levels of PD-1, PD-L1 and PD-L2 on four lymphocyte subsets 12 
(CD27+CD19+ B cells, CD27-CD19+ B cells, CD27+CD4+ T cells and CD27-CD4+ T cells) were 13 
compared between 22 sepsis patients (including 11 survivors and 11 non-survivors) and 11 14 
healthy controls using flow cytometry. Levels of soluble PD-1 and PD-L1 were also compared 15 
using commercially available ELISA kits. 16 
Results: Expression of PD-1 and PD-L1 was higher on all lymphocyte subsets in sepsis 17 
patients compared to controls (p<0.05). PD-L2 expression on CD27+ B cells was also higher 18 
in sepsis patients (p=0.0317). There was differential expression of PD-1 by CD27 status, with 19 
expression being higher in the B and T cell subsets associated with memory status (CD27+ 20 
and CD27-, respectively; p<0.001). Higher PD-1 and PD-L1 expression was not associated 21 
with mortality nor with a higher risk of nosocomial infections. There were no differences in 22 
levels of soluble PD-1 or PD-L1 between sepsis patients and controls. 23 
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Conclusions: Higher expression of PD-1 by memory subpopulations of B cells and CD4+ T 1 
cells, with normal soluble PD-1 and PD-L1 in sepsis patients, are novel findings. This 2 
information may be useful to enrich sepsis populations for trials of PD-1/PD-L1 blockade. 3 
Keywords: sepsis, septic shock, Programmed death-1, enrichment, outcomes 4 
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Background 1 
Sepsis is a dysregulated host response to infection [1], with concomitant immune activation 2 
and suppression. Sepsis-related immunosuppression contributes to poor outcomes by 3 
increasing the risk of nosocomial infection and death [2-4]. A common feature of sepsis-4 
related immunosuppression is impaired lymphocyte function, with increased expression of 5 
inhibitory checkpoint molecules, such as programmed-death 1 protein (PD-1) [2]. PD-1 6 
serves to limit excessive immune responses by negatively regulating lymphocyte activation 7 
and function, and promoting immune cell apoptosis. It has two known ligands: programmed 8 
death ligand-1 (PD-L1), which is widely expressed by a variety of immune and non-immune 9 
cell types; and programmed death ligand-2 (PD-L2), which is expressed by antigen-10 
presenting cells [2]. Increased expression of PD-1 and PD-L1 by T cells, monocytes and 11 
neutrophils has been demonstrated in sepsis, while upregulation of the PD-1 pathway is 12 
associated with higher mortality [2, 5-8]. As this dysfunction is potentially reversible with 13 
anti-PD-1 or anti-PD-L1 monoclonal antibody treatment [2, 5-8], manipulating the PD-1 14 
pathway represents a potential target for sepsis trials.  15 
Against this background, we hypothesized that lymphocyte surface PD-1, PD-L1 and PD-L2 16 
expression by B and T cell subsets will vary by CD27 expression status. CD27 is a marker of 17 
lymphocyte activation; CD27 positive (CD27+) B cells correspond to memory B cells [9], 18 
while CD27 negative (CD27-) T cells represent a high antigen-recall subset of memory T cells 19 
[10]. Another rationale for assessing CD27 based memory lymphocyte subsets is the  20 
selective depletion of memory B cells in sepsis [8]; it is not known whether PD-1 expression 21 
varies by lymphocyte memory status. We therefore measured PD-1, PD-L1 and PD-L2 22 
surface expression on CD27+ and CD27- subsets of CD4+ T and B lymphocytes using flow 23 
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cytometry in adult patients with sepsis on the intensive care unit (ICU). We compared 1 
expression between sepsis and healthy controls, and between subgroups of sepsis patients 2 
by nosocomial infection and survival status. PD-1 and PD-L1 also exist in a soluble form in 3 
the serum, however the relevance of these soluble forms to sepsis pathogenesis is unclear. 4 
We hypothesized that cell-surface PD-1, PD-L1 and PD-L2 expression would correlate with 5 
serum concentrations, and so measured corresponding serum PD-1 and PD-L1 levels in the 6 
same samples. 7 
 8 
Methods 9 
Conceptual approach 10 
Immune responses in sepsis differ between patients [3, 4]. The ability to identify who would 11 
– or would not – benefit from a therapy based on specific biological mechanisms, will offer a 12 
crucial step forward in patient management, especially when that mechanism is dominant, 13 
linked to an outcome of interest, and present at the time of assessment of trial eligibility 14 
[11]. These principles informed our study design. Our conceptual approach was that sepsis 15 
trial eligibility criteria assessments are often done on the day of ICU admission and that 16 
patients with increased expression of PD-1 and PD-L1 have a greater risk of nosocomial 17 
infections and/or death, as this would be a dominant mechanism contributing to these 18 
outcomes. 19 
Study design and setting 20 
This was an analysis of a subpopulation of patients enrolled into a previous prospective 21 
observational cohort study performed in a general medical-surgical tertiary ICU (HRA 22 
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Research Ethics Committee approval reference: 12/LO/0326). Details of the study design 1 
have been published previously [8, 12]. From this cohort we randomly selected 22 adult 2 
patients with sepsis, with an ICU length of stay ≥48 hours, and included equal numbers of 3 
survivors and non-survivors [8, 12]. As our original study was designed prior to the Sepsis-3 4 
definitions, sepsis was identified using the previous definition requiring proven or suspected 5 
infection, two or more systemic inflammatory response system (SIRS) criteria, and at least 6 
one organ system dysfunction (cardiovascular, respiratory, renal, hematologic, hepatic, 7 
neurologic or metabolic) [13]. We highlighted in a recent cohort study that the prevalence 8 
of SIRS negative sepsis in ICU patients in England was approximately 3% [14], with a 92% 9 
overlap in sepsis cases identified by Sepsis-2 and Sepsis-3 [15]. We excluded patients less 10 
than 18 years old, and those with known immune dysfunction, including; those with 11 
congenital hypogammaglobulinemia, known protein-losing enteropathies, nephrotic 12 
syndrome, and neoplastic or proliferative hematologic diseases; those having received 13 
intravenous immunoglobulin therapy in the last 3 months; those receiving high-dose 14 
corticosteroid therapy; those with ongoing blood loss (defined by blood transfusion 15 
requirement > 2 units in a 24 hour period); those with retroviral disease; and those with 16 
immune dysfunction as defined by Acute Physiology and Chronic Health Evaluation 17 
(APACHE) II score comorbidities [16]. 18 
Blood sampling, flow cytometry, ELISA and healthy controls 19 
Peripheral blood mononuclear cells were isolated by density centrifugation from blood 20 
samples collected within 12 hours of ICU admission, and stored in liquid nitrogen. Serum 21 
samples from the same patients were stored at -80°C. Anti-human fluorochromes were used 22 
to identify lymphocyte subsets: anti-CD19 (PerCP Cy5.5; HB19); anti-CD3 (APC-H7; SK7) 23 
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(both BD Biosciences, Wokingham, Berkshire, UK); anti-CD4 (Pacific Blue; SK3); anti-CD27 1 
(FITC; 0323); anti-PD-1 (APC; EH12.2H7); anti-PD-L1 (PeCy7; 29E.2A3); and anti-PD-L2 (PE; 2 
24F.101C12) (all Biolegend, London, UK). Amcyan (L34957; Invitrogen, Carlsbad, CA) was 3 
used to identify live cells. All flow cytometry experiments were carried out by the same 4 
investigator. Flow cytometer set up, calibration and compensation were carried out prior to 5 
each experiment using BD CompBeads (BD Biosciences). Reagents remained the same 6 
during the course of the study. Gating to identify cell subsets was achieved using isotype 7 
controls and fluorescence minus-one (FMO) controls (eFigure-1). FlowJo software 8 
(https://www.flowjo.com) was used for analysis of flow cytometry data. Percentage 9 
positivity for PD-1, PD-L1 and PD-L2 was defined as the percentage of cells above the gate 10 
set using the above controls, with the proportion of positive cells and the corresponding 11 
geometric mean fluorescence intensity (MFI) used as indicators of expression. Quantitative 12 
detection of serum levels of PD-1 and PD-L1 was done in duplicate using commercial ELISA 13 
kits (Proteintech, Manchester, UK), according to the manufacturer’s instructions. Detection 14 
ranges for PD-1 and PD-L1 were 125-8000 pg/ml and 0.156-10 ng/ml, respectively. All flow 15 
cytometry and ELISA experiments used anonymised healthy controls who were consented 16 
prior to sampling as per the King’s College London Infectious Diseases Biobank protocol [8]. 17 
Statistics 18 
Mann-Whitney U tests were used to compare PD-1, PD-L1 and PD-L2 expression on B and T 19 
cells between septic patients and controls, and between subgroups of septic patients based 20 
on mortality and nosocomial infection status, with nosocomial infection defined as a new 21 
antibiotic start for suspected new infection, after an antibiotic-free period of ≥24 hours. 22 
Within sepsis patients, PD-1, PD-L1 and PD-L2 expression on B and T cells was compared by 23 
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CD27 status using the paired Wilcoxon test. All statistical analyses were performed with 1 
GraphPad Prism software (GraphPad Software, La Jolla, CA). Significance levels were set as p 2 
values <0.05. 3 
 4 
Results 5 
Study cohort 6 
The median (IQR) age of the septic patients was 68.5 (54.8 – 84.3) years, with 73% being 7 
male. The respiratory tract was the most common infection site (73%), followed by intra-8 
abdominal (18%) and wound/soft tissue (9%). The mean (SD) total white cell and 9 
lymphocyte counts were 15.9 (7.8) x 109 cells/litre and 1.1 (0.7) x 109 cells/litre, respectively. 10 
The median (IQR) ICU length of stay was 10.5 (7 – 20) days. Nosocomial infection occurred in 11 
11 patients and was more common in patients with an ICU length of stay ≥4 days (61% vs 12 
0%). Patient characteristics are summarized in eTables 1 and 2.  13 
Memory B cells in sepsis patients had more PD-1, PD-L1 and PD-L2 positive cells with 14 
higher expression 15 
The proportion of B cells positive for PD-1, and the corresponding MFI, were significantly 16 
higher in sepsis patients than in controls (26.5% vs 8.8%, p=0.0002; 483 vs 348, p=0.0003) 17 
(eTable 3; Figure 1). This was true of both CD27+ and CD27- subsets (eTable 4; eFigure 2; 18 
eFigure 3). The proportion of PD-L1 positive B cells was also higher in sepsis patients 19 
compared to healthy controls (2.4% vs 1.2%, p=0.0244). The percentage positivity of PD-L2 20 
was higher in sepsis than controls in the CD27+ subset only (3.59% vs 0.41%, p=0.0317) 21 
(eFigure 3). Within B cells in septic patients, the CD27+ subset had significantly higher PD-1 22 
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and PD-L2 MFI (574.5 vs 471.5, p<0.0001; 1189 vs 744, p<0.0001) and percentage positivity 1 
(34.05% vs 24.80%, p<0.0007; 3.59% vs 0.86%, p<0.0001) (Figure 1). 2 
Memory CD4+ T cells in sepsis patients had more PD-1, PD-L1 and PD-L2 positive cells with 3 
higher expression 4 
The proportions of PD-1 and PD-L1 positive T cells were significantly higher in sepsis than in 5 
controls (38.90% vs 21.25%, p=0.0023; 1.9% vs 0.2%, p=0.0083), as were the corresponding 6 
MFI values (780 vs 627, p=0.0013; 1314 vs 1007, p=0.0276) (Figure 2). This was true of 7 
CD27+ and CD27- subsets (p<0.05 for all comparisons) (eTable 4; eTable 5; eFigure 4; 8 
eFigure 5). There were no significant differences in CD4+ T cell PD-L2 expression between 9 
sepsis and healthy controls. In sepsis patients, expression of PD-1 was higher on CD27- T 10 
cells than CD27+ T cells, by both percentage positivity and MFI (70.45% vs 35.15%, 11 
p<0.0001; 972 vs 716, p<0.0001) (Figure 2). 12 
Admission day PD-1, PD-L1 and PD-L2 expression did not differ by nosocomial infection 13 
and hospital mortality 14 
There were no differences in PD-1, PD-L1 or PD-L2 expression between patients who 15 
subsequently developed a nosocomial infection and those who did not (eFigure 6). When 16 
patients with an ICU length of stay ≤7 days were excluded, PD-L1 expression on lymphocytes 17 
was significantly higher in those who subsequently developed an infection (p=0.0068) 18 
(eFigure 7), however this did not reach significance for any B or T cell subset (eFigure 8). 19 
There were no differences between survivors and non-survivors in PD-1, PD-L1 or PD-L2 20 
expression for any lymphocyte subset (eFigure 9).  21 
Soluble PD-1 and PD-L1 expression did not correlate with cell surface expression 22 
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There were no differences in serum sPD-1 and sPD-L1 concentrations between sepsis 1 
patients and healthy controls (eFigure 10). Serum sPD-1 and sPD-L1 concentrations in sepsis 2 
patients showed no correlation to lymphocyte surface expression (eFigure 11). 3 
 4 
Discussion 5 
The novel findings from this pilot study include the first report of higher B cell expression of 6 
PD-1, PD-L1 and PD-L2 in sepsis, and a differential expression of PD-1 by CD27 status in both 7 
B and CD4+ T cells. We also report results that are consistent with the published literature 8 
such as higher PD-1 and PD-L1 expression in CD4+ T cells in sepsis compared with controls 9 
[7, 17], which gives external validity to our report. The overexpression of these checkpoint 10 
inhibitors in most sepsis patients is consistent with the published literature suggesting this is 11 
a feature of sepsis-related immunosuppression.  12 
PD-L2 has been less well-studied in sepsis than PD-L1, as PD-L1 is the more important 13 
binding partner for PD-1. The contribution of PD-L2 to the pathophysiology of sepsis 14 
remains unknown although increased PD-L2 expression by monocytes was reported in one 15 
observational study of patients with septic shock [7]. A key finding of our present study in 16 
critically ill adult patients with sepsis was a higher expression of PD-1/PD-L in the 17 
lymphocyte subsets associated with memory status, i.e. CD27+ B cells and CD27- CD4+ T 18 
cells. Memory lymphocytes are formed after encountering a specific pathogen, and are vital 19 
for generating rapid and effective immune responses upon future encounters with the same 20 
pathogen [18]. We chose CD27 as a marker of memory status. In circulating B cells, CD27 21 
expression is associated with activation [9]. CD27+ B cells are larger in size and exhibit 22 
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greater and more rapid proliferation and immunoglobulin production in response to 1 
antigenic stimulation [9]. In CD4+ T cells, loss of CD27 expression is seen in memory cells at 2 
a late stage in differentiation, and is associated with an increased capacity for IL-4 3 
production [19]. Functional studies of CD4+ T cells report that CD27 expression distinguishes 4 
two distinct subpopulations, of which the CD27- subset shows a stronger antigen-recall 5 
response and increased cytokine secretion [10]. A relatively higher PD-1 expression on 6 
CD27- T cells may therefore have a greater negative effect on antigen-specific responses in 7 
both B cells and T cells, as there is T cell-dependent B cell development within the germinal 8 
centres of secondary lymphoid organs [20].  9 
We measured soluble PD-1 and PD-L1 levels as high levels of sPD-1 or sPD-L1 in sepsis could 10 
reduce the efficacy of anti-PD-1 or anti-PD-L1 antibody therapy by neutralisation. 11 
Furthermore, should serum levels correlate with cell surface expression, this may offer a 12 
potential point-of-care biomarker to identify patients who could benefit from early PD-1 13 
pathway blockade. We did not find any significant differences in sPD-1 or sPD-L1 levels 14 
between sepsis patients and controls; of note, levels were towards the lower limit of 15 
detection in the majority of subjects. Previous studies measuring serum sPD-1/L levels in 16 
sepsis have yielded inconsistent results [21-23] (eTable-6). Importantly, none of these 17 
studies measured concurrent cell surface expression. Timing of measurement may 18 
contribute to the differences; we measured sPD-1/PD-L1 within 12 hours of ICU admission 19 
whereas the others varied from time of presentation to the emergency department [21] to 20 
within 24 hours of ICU admission [22, 23]. Our pilot study results suggest that sPD-1 or sPD-21 
L1 levels within 12 hours of ICU admission do not identify patients with high cell surface PD-22 
1/L expression [11]. This needs confirmation in larger cohorts, ideally using the same 23 
inclusion criteria to those planned for interventional trials. 24 
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In contrast to one previous study [7], we did not observe significant differences in PD-1/PD-1 
L1 expression by either survival or nosocomial infection status. Aside from our small sample 2 
size, there are several alternative explanations. The kinetics of these checkpoint inhibitors in 3 
critically ill sepsis patients are unknown. There is also a variable degree of 4 
immunosuppression even at the time of ICU admission though we specifically excluded any 5 
patients with previously documented immunosuppression. However, our timing of sampling 6 
within 12 hours of ICU admission may be too early for differentiating survival status. This 7 
inference is supported by a recent study examining PD-1 expression by CD4+ T cells in a 8 
sepsis cohort using serial measurements on days 1, 3 and 7 of ICU admission, which found 9 
that while all septic patients had raised PD-1 at days 1 and 3, only survivors normalised PD-1 10 
expression by day 7 [17]. This highlights the need for further work to characterize how PD-11 
1/L expression changes over the course of sepsis, how this relates to outcome, and the 12 
optimal recruitment window for any future trial of anti-PD-1 therapy. With regard to 13 
nosocomial infection, we found that lymphocyte PD-L1 expression was significantly higher in 14 
those who subsequently developed an infection, but only when the ICU length of stay 15 
exceeded 7 days. This may be explained by the competing risk of nosocomial infection with 16 
early ICU discharge or death. The additional risk provided by over-expression of these 17 
checkpoint inhibitors may be overwhelmed by stronger risk factors for mortality such as 18 
age, comorbidity and illness severity [14].  19 
When interpreting our results, key limitations to consider include the small sample size, the 20 
use of healthy controls instead of non-sepsis critical illness controls, and that this was a 21 
post-hoc sub-study designed to test a hypothesis to inform future trials. We chose healthy 22 
controls as critically ill patients exhibit a range of immune deficits similar to those seen in 23 
sepsis patients [24]; the use of non-infected critically ill controls could confound the 24 
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association between PD-1 expression and outcomes. The key strengths of the study include 1 
the hypothesis-driven set of experiments that highlight the need for further research to 2 
define PD-1, PD-L1 and PD-L2 expression in sepsis, and its relationship to two competing 3 
events: nosocomial infection and death [11]. 4 
 5 
Conclusions 6 
In conclusion, our pilot study contributes to the further understanding of sepsis immunology 7 
by highlighting increased expression of these checkpoint regulators in B cells, and their 8 
differential expression by memory subset status in both B and T cells. The utility of CD27 9 
status in lymphocytes as a putative biomarker for patient enrichment in anti PD-1 or anti 10 
PD-L1 trials warrants further study.  11 
 12 
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ELISA: enzyme-linked immunosorbent assay; FCS: flow cytometry standard; FMO: 14 
fluorescence minus one; ICU: intensive care unit; MFI: mean fluorescence intensity; PD-1: 15 
programmed death protein 1; PD-L1: programmed death-ligand 1; PD-L2: programmed 16 
death-ligand 2; SD: standard deviation; sPD-1: soluble programmed death protein 1; sPD-L1: 17 
soluble programmed death-ligand 1 18 
 19 
Declarations 20 
Ethics approval and consent to participate 21 
14 
 
All patients who met the eligibility criteria were consented prior to blood sampling. Ethics 1 
approval for the study was given by HRA Research Ethics Committee London (Camberwell St 2 
Giles). Address: East of England REC Centre Victoria House, Capital Park Fulbourn, 3 
Cambridge CB21 5XB. Approval reference: 12/LO/0326. 4 
Consent for publication 5 
Not applicable 6 
Availability of data and material 7 
The datasets generated and/or analysed during the current study are available from the 8 
corresponding author on reasonable request. 9 
Competing interests 10 
MS is on the steering committee for a clinical trial of anti PD-L1 therapy in sepsis. The other 11 
authors have no competing interests to declare. 12 
Funding 13 
MSH is supported by the UK National Institute for Health Research Clinician Scientist Award 14 
(NIHR-CS-2016-16-011). MS is supported by a UK National Institute for Health Research 15 
Senior Investigator Award. JW is an NIHR Academic Clinical Fellow in Intensive Care 16 
medicine. The views expressed in this publication are those of the author(s) and not 17 
necessarily those of the NHS, the NIHR, or the UK Department of Health. 18 
Authors’ contributions 19 
JW performed the flow cytometry and ELISA experiments and analysed the data. MSH 20 
designed the study, and obtained the samples. MSH and JW wrote the first version of the 21 
15 
 
manuscript. JS and YZ supervised the laboratory experiments, including ELISA and flow 1 
cytometry. All authors read, and approved the final manuscript. 2 
Acknowledgements 3 
Not applicable 4 
16 
 
References 1 
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, 2 
Bernard GR, Chiche JD, Coopersmith CM et al: The Third International Consensus 3 
Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016, 315(8):801-810. 4 
2. Hotchkiss RS, Monneret G, Payen D: Sepsis-induced immunosuppression: from cellular 5 
dysfunctions to immunotherapy. Nat Rev Immunol 2013, 13(12):862-874. 6 
3. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, 7 
Nurnberg P, Schultz MJ, Horn J, Cremer OL et al: Classification of patients with sepsis 8 
according to blood genomic endotype: a prospective cohort study. The Lancet Respiratory 9 
medicine 2017. 10 
4. van der Poll T, van de Veerdonk FL, Scicluna BP, Netea MG: The immunopathology of sepsis 11 
and potential therapeutic targets. Nat Rev Immunol 2017, 17(7):407-420. 12 
5. Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S, Robbins P, Ulbrandt N, 13 
Suzich J, Green J et al: Targeting the programmed cell death 1: programmed cell death 14 
ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014, 15 
18(1):R3. 16 
6. Patera AC, Drewry AM, Chang K, Beiter ER, Osborne D, Hotchkiss RS: Frontline Science: 17 
Defects in immune function in patients with sepsis are associated with PD-1 or PD-L1 18 
expression and can be restored by antibodies targeting PD-1 or PD-L1. J Leukoc Biol 2016, 19 
100(6):1239-1254. 20 
7. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Chéron A, 21 
Allaouchiche B, Gueyffier F et al: Programmed death-1 levels correlate with increased 22 
mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit 23 
Care 2011, 15(2):R99. 24 
8. Shankar-Hari M, Fear D, Lavender P, Mare T, Beale R, Swanson C, Singer M, Spencer J: 25 
Activation-Associated Accelerated Apoptosis of Memory B Cells in Critically Ill Patients 26 
With Sepsis. Crit Care Med 2017, 45(5):875-882. 27 
9. Tangye SG, Good KL: Human IgM+CD27+ B cells: memory B cells or "memory" B cells? J 28 
Immunol 2007, 179(1):13-19. 29 
10. Schiott A, Lindstedt M, Johansson-Lindbom B, Roggen E, Borrebaeck CA: CD27- CD4+ 30 
memory T cells define a differentiated memory population at both the functional and 31 
transcriptional levels. Immunology 2004, 113(3):363-370. 32 
11. Shankar-Hari M, Rubenfeld GD: The use of enrichment to reduce statistically indeterminate 33 
or negative trials in critical care. Anaesthesia 2017, 72(5):560-565. 34 
12. Shankar-Hari M, Singer M, Spencer J: Can Concurrent Abnormalities in Free Light Chains 35 
and Immunoglobulin Concentrations Identify a Target Population for Immunoglobulin 36 
Trials in Sepsis? Crit Care Med 2017, 45(11):1829-1836. 37 
13. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, 38 
Ramsay G et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions 39 
Conference. Crit Care Med 2003, 31(4):1250-1256. 40 
14. Shankar-Hari M, Harrison DA, Rowan KM: Differences in Impact of Definitional Elements on 41 
Mortality Precludes International Comparisons of Sepsis Epidemiology-A Cohort Study 42 
Illustrating the Need for Standardized Reporting. Crit Care Med 2016, 44(12):2223-2230. 43 
15. Shankar-Hari M, Harrison DA, Rubenfeld GD, Rowan K: Epidemiology of sepsis and septic 44 
shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a 45 
national critical care database. Br J Anaesth 2017, 119(4):626-636. 46 
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease 47 
classification system. Crit Care Med 1985, 13(10):818-829. 48 
17 
 
17. Tomino A, Tsuda M, Aoki R, Kajita Y, Hashiba M, Terajima T, Kano H, Takeyama N: Increased 1 
PD-1 Expression and Altered T Cell Repertoire Diversity Predict Mortality in Patients with 2 
Septic Shock: A Preliminary Study. PLoS One 2017, 12(1):e0169653. 3 
18. Kurosaki T, Kometani K, Ise W: Memory B cells. Nat Rev Immunol 2015, 15(3):149-159. 4 
19. Fritsch RD, Shen X, Sims GP, Hathcock KS, Hodes RJ, Lipsky PE: Stepwise differentiation of 5 
CD4 memory T cells defined by expression of CCR7 and CD27. J Immunol 2005, 6 
175(10):6489-6497. 7 
20. De Silva NS, Klein U: Dynamics of B cells in germinal centres. Nat Rev Immunol 2015, 8 
15(3):137-148. 9 
21. Zhao Y, Jia Y, Li C, Fang Y, Shao R: The risk stratification and prognostic evaluation of 10 
soluble programmed death-1 on patients with sepsis in emergency department. Am J 11 
Emerg Med 2018, 36(1):43-48. 12 
22. Liu M, Zhang X, Chen H, Wang G, Zhang J, Dong P, Liu Y, An S, Wang L: Serum sPD-L1, 13 
Upregulated in Sepsis, May Reflect Disease Severity and Clinical Outcomes in Septic 14 
Patients. Scand J Immunol 2017, 85(1):66-72. 15 
23. Lange A, Sunden-Cullberg J, Magnuson A, Hultgren O: Soluble B and T Lymphocyte 16 
Attenuator Correlates to Disease Severity in Sepsis and High Levels Are Associated with an 17 
Increased Risk of Mortality. PLoS One 2017, 12(1):e0169176. 18 
24. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, Hayden DL, Hennessy L, 19 
Moore EE, Minei JP et al: A genomic storm in critically injured humans. J Exp Med 2011, 20 
208(13):2581-2590. 21 
 22 
 23 
Additional files 24 
eTable 1. Sepsis patient characteristics 25 
eTable_1.docx 26 
Table showing characteristics of sepsis patients included in the study. Figures are shown for 27 
all patients, and for survivors and non-survivors 28 
 29 
eTable 2. Infection site/microbiology of patients with nosocomial infections 30 
eTable_2.docx 31 
Table showing the survival status, microbiology results and nosocomial infection site of 32 
those patients who developed nosocomial infection. 33 
 34 
eTable 3. Proportion of positive B and T cells 35 
eTable_3.docx 36 
Table showing the proportion of B and CD4+ T cells which express PD-1, PD-L1 and PD-L2, 37 
compared between sepsis patients and healthy controls. 38 
18 
 
 1 
eTable 4. Proportion of positive cells by CD27 expression status 2 
eTable_4.docx 3 
Table showing the proportion of CD27+ B cells, CD27- B cells, CD27+ CD4+ T cells and CD27- 4 
CD4+ T cells which express PD-1, PD-L1 and PD-L2, compared between sepsis patients and 5 
healthy controls. 6 
 7 
eTable 5. MFI results 8 
eTable_5.docx 9 
Table showing the MFI of PD-1, PD-L1 and PD-L2 on CD27+ B cells, CD27- B cells, CD27+ 10 
CD4+ T cells and CD27- CD4+ T cells, compared between sepsis patients and healthy 11 
controls. 12 
 13 
eTable 6. sPD-1/sPD-L1 studies in sepsis 14 
eTable_6.docx 15 
Summary of previous studies measuring soluble serum PD-1 and PD-L1 (sPD-1; sPD-L1) 16 
levels in sepsis. 17 
 18 
eFigure 1. Example of gating used in data analysis 19 
eFigure_1.docx 20 
The isotype (and FMO) was used to set the negative gate, and then the percentage of 21 
positive cells was taken as the percentage above this gate. Separate healthy and sepsis 22 
isotypes were used (eFigure 1a and 1b respectively). 1c shows an example of MFI signalling 23 
in healthy and sepsis isotypes, and healthy, sepsis survivor and sepsis non-survivor samples. 24 
 25 
eFigure 2. B cell subset MFI 26 
eFigure_2.docx 27 
Box and whisker plots comparing expression by MFI of PD-1, PD-L1 and PD-L2 between 28 
sepsis patients and healthy controls on B cell subsets (CD27+ and CD27-). 29 
 30 
eFigure 3. B cell percentage positivity 31 
eFigure_3.docx 32 
Dot plots comparing the expression levels by percentage positivity of PD-1, PD-L1 and PD-L2 33 
between sepsis patients and healthy controls on B cell subsets (CD27+ and CD27-). 34 
19 
 
 1 
eFigure 4. CD4+ T cell subset MFI 2 
eFigure_4.docx 3 
Box and whisker plots comparing expression by MFI of PD-1, PD-L1 and PD-L2 between 4 
sepsis patients and healthy controls on CD4+ T cell subsets (CD27+ and CD27-). 5 
 6 
eFigure 5. CD4+ T cell percentage positivity 7 
eFigure_5.docx 8 
Dot plots comparing the expression levels by percentage positivity of PD-1, PD-L1 and PD-L2 9 
between sepsis patients and healthy controls on CD4+ T cell subsets (CD27+ and CD27-). 10 
 11 
eFigure 6. Comparison by nosocomial infection status 12 
eFigure_6.docx 13 
Box and whisker plots comparing expression of PD-1, PD-L1 and PD-L2 between patients 14 
who developed a nosocomial infection and those who did not. 15 
 16 
eFigure 7. PD-L1 comparison by nosocomial infection status in patients with ICU length of 17 
stay ≥7 days 18 
eFigure_7.docx 19 
Box and whisker plot showing PD-L1 expression by lymphocytes compared between patients 20 
who developed a nosocomial infection and those who did not, when patients with an ICU 21 
length of stay less than 7 days are excluded. 22 
 23 
eFigure 8. Comparison by nosocomial infection status in patients with ICU length of stay 24 
≥7 days 25 
eFigure_8.docx 26 
Box and whisker plots comparing PD-1, PD-L1 and PD-L2 expression by B and CD4+ T cells 27 
between patients who developed a nosocomial infection and those who did not, when 28 
patients with an ICU length of stay less than 7 days are excluded. 29 
 30 
eFigure 9. Comparison by survival status 31 
eFigure_9.docx 32 
Box and whisker plots comparing PD-1, PD-L1 and PD-L2 expression by B and CD4+ T cells 33 
between sepsis survivors and non-survivors. 34 
20 
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eFigure 10. Serum level comparison 2 
eFigure_10.docx 3 
Dot plots comparing levels of serum PD-1 and PD-L1 between sepsis patients and healthy 4 
controls. 5 
 6 
eFigure 11. Serum vs cell surface expression 7 
eFigure_11.docx 8 
Scatter graphs plotting serum levels of PD-1 and PD-L1 against cell surface expression levels 9 
on B cells and CD4+ T cells. 10 
 11 
 12 
Figure titles/legends 13 
Figure 1. PD-1/L expression on B cells.  14 
Box and whisker plots (Figure 1a-c) comparing the MFI of PD-1, PD-L1 and PD-L2 on B cells in 15 
sepsis patients compared with healthy controls. Figure 1d-f compares the MFI of PD-1, PD-16 
L1 and PD-L2 between CD27+ B cells and CD27- B cells within sepsis patients. The boxes 17 
below show the corresponding proportion of positive cells for each comparison, with 18 
corresponding p-values. Significant p-values are marked with an asterisk.  19 
 20 
Figure 2. PD-1/L expression on CD4+ T cells.  21 
Box and whisker plots (Figure 2a-c) comparing the MFI of PD-1, PD-L1 and PD-L2 on T cells in 22 
sepsis patients compared with healthy controls. Figure 2d-f compares the MFI of PD-1, PD-23 
L1 and PD-L2 between CD27+ T cells and CD27- T cells within sepsis patients. The boxes 24 
below show the corresponding proportion of positive cells for each comparison, with 25 
corresponding p-values. Significant p-values are marked with an asterisk.  26 
21 
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